WILLARD BEARD: Open Payments
NPI 1598916330 · PINEVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,112 in 120 payments from 21 companies in 2025. Trend: 2023 $1,387 · 2024 $1,652 · 2025 $2,112
Food & beverage: $2,112
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $385 |
| AstraZeneca Pharmaceuticals LP | 15 | $301 |
| Novo Nordisk Inc | 16 | $261 |
| Lilly USA, LLC | 13 | $203 |
| Otsuka America Pharmaceutical, Inc. | 9 | $173 |
| GlaxoSmithKline, LLC. | 8 | $139 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $94 |
| Kowa Pharmaceuticals America, Inc. | 5 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| PFIZER INC. | 3 | $61 |
Products named: REXULTI, QULIPTA, MOUNJARO, JARDIANCE, TRELEGY ELLIPTA, FARXIGA, VRAYLAR, UBRELVY.
Industry payments across LA — which companies pay providers there.
